Early Targeted C1q Inhibition With Tanruprubart Improves Functional Recovery in Guillain-Barré Syndrome: Results From a Phase Three Study (S21.002)

Key Points

• This research aims to evaluate if C1q inhibition using tanruprubart enhances functional recovery in Guillain-Barré syndrome.
• Phase three clinical trial with C1q inhibition intervention
• Evaluated early treatment effects and axonal damage severity
• Target population included patients with Guillain-Barré syndrome
• Tanruprubart improved functional recovery scores compared to control; exact metrics unspecified
• Earlier treatment correlated with better outcomes in patients showing limited axonal damage.